DigestRedComo funciona
Red
/
Empresas
Ve
No verificado

VectorY Therapeutics

Sobre qué escribimos

BiotecnologíaCienciaFarmacéuticaMedicina - VariosSalud

11 Comunicados de prensa

Ver todos los comunicados de prensa
09/02/2026
Industria
Ciencia
Biotecnología
Farmacéutica
Salud
Medicina - Varios
VectorY Therapeutics Announces First Participant Dosed in Phase 1/2 PIONEER-ALS Clinical Trial of VTx-002 in People with Amyotrophic Lateral Sclerosis (ALS)
Fuente
VectorY Therapeutics
Editor
Business Wire
1.00
0
05/02/2026
Ciencia
Biotecnología
Farmacéutica
Sanidad
Salud
Medicina - Varios
Mercado laboral
VectorY Therapeutics Appoints Kevin Pojasek, Ph.D., to Board of Directors
Fuente
VectorY Therapeutics
Editor
Business Wire
1.00
0
08/01/2026
Industria
Ciencia
Higiene alimentaria
Medicina - Varios
Biotecnología
Salud
Farmacéutica
VectorY Therapeutics Receives FDA Fast Track Designation for VTx-002, a First-in-Class Vectorized Antibody Targeting Underlying Disease Biology in ALS
Fuente
VectorY Therapeutics
Editor
Business Wire
1.00
0
03/12/2025
Ciencia
Higiene alimentaria
Medicina - Varios
Biotecnología
Salud
Farmacéutica
Sanidad
Industria
VectorY Therapeutics Receives FDA Clearance of IND to Proceed with the PIONEER-ALS Phase 1/2 Trial of VTx-002, a First-in-Class Vectorized Antibody Targeting TDP-43 Pathology in ALS
Fuente
VectorY Therapeutics
Editor
Business Wire
1.00
0
18/09/2025
Salud
Biotecnología
Ciencia
Farmacéutica
Mercado laboral
Industria
VectorY Therapeutics and Shape Therapeutics Announce Option and License Agreement to Advance Vectorized Antibodies for Neurodegenerative Diseases Using an AAV5-Derived CNS Capsid
Fuente
VectorY Therapeutics
Editor
Business Wire
1.00
0
27/05/2025
VectorY Therapeutics Appoints Jessica Atkinson as Chief Business Officer
Fuente
VectorY Therapeutics
Editor
Business Wire
1.00
0
07/05/2025
Eventos
Biotecnología
Salud
Medicina - Varios
VectorY Therapeutics to Present Preclinical Data on Novel ALS Therapeutic Strategy at Target ALS Conference in Boston
Fuente
VectorY Therapeutics
Editor
Business Wire
1.00
0
29/04/2025
Eventos
Industria
Ciencia
Biotecnología
Medicina - Varios
Sanidad
Farmacéutica
Salud
VectorY Therapeutics Announces Multiple Presentations at Upcoming American Society of Gene and Cell Therapy Annual Meeting 2025
Fuente
VectorY Therapeutics
Editor
Business Wire
1.00
0
01/04/2025
VectorY Therapeutics Appoints Olga Uspenskaya-Cadoz as Chief Medical Officer
Fuente
VectorY Therapeutics
Editor
Business Wire
1.00
0
16/12/2024
Multimedia
Biotecnología
Farmacéutica
Ciencia
Mercado laboral
VectorY Strengthens Leadership Team with Appointment of Jim Scibetta as New CEO
Fuente
VectorY Therapeutics
Editor
Business Wire
1.00
0

Detalles de contacto

Redes sociales

Seguidores
0
Compatibilidad
0